top of page
Search

Lynch Syndrome UK Joins Cancer52

  • Apr 14
  • 2 min read

Strengthening the Voice for Hereditary and Less Common Cancers


We’re pleased to share that Lynch Syndrome UK has become a member of Cancer52 - a network of over 100 charities united by a shared mission: to improve outcomes for people affected by rare and less common cancers.


What is Cancer52?

Cancer52 brings together patient organisations representing cancers outside the “big four” — breast, prostate, lung and bowel.


cancer52 logo

These cancers are often less visible in public conversation and can face challenges such as later diagnosis, fewer treatment options, and more limited access to support.


Cancer52 works to address these gaps by advocating for:

  • Earlier and more accurate diagnosis

  • Improved treatment and care pathways

  • Stronger support for patients and families

  • Greater recognition in policy and research


Why this matters for the Lynch syndrome community

Lynch syndrome increases the risk of several cancers, including bowel, endometrial, ovarian and others, many of which fall into the “less common” category when considered individually.


This means that people with Lynch syndrome can experience some of the same challenges seen across the rare cancer community:

  • Delays in diagnosis or referral

  • Variability in access to genetic testing and surveillance

  • Differences in awareness across healthcare settings


By joining Cancer52, Lynch Syndrome UK is strengthening its ability to ensure that hereditary cancer risk is part of the wider conversation about rare and less common cancers.


A shared mission: improving prevention and early detection

At Lynch Syndrome UK, our work focuses on improving awareness, supporting individuals and families, and advocating for equitable access to genetic testing and risk-reducing care.


Through Cancer52, we will collaborate with clinicians, researchers and policymakers to:

  • Promote earlier identification of inherited cancer risk

  • Improve access to genetic services across the UK

  • Support informed decision-making for patients and families

  • Ensure that lived experience shapes future healthcare planning


Commenting on the partnership, Lynch Syndrome UK Trustee, Tracy Smith, said "As Chair of Lynch Syndrome UK, I’m delighted for us to join Cancer52 and to stand alongside such a committed community working to improve outcomes for people affected by rare and less common cancers. Collaboration is essential if we are to raise awareness, influence policy, and ensure equitable access to testing, early detection, and support across all UK nations. I very much look forward to contributing to this collective effort and strengthening our shared voice for those living with inherited and rare cancer risk."

Stronger together

Joining Cancer52 means being part of a collective voice — one that is working to ensure no cancer is overlooked simply because it is less common.


For our community, this is an important step forward. It strengthens our ability to advocate for better care, raise awareness of Lynch syndrome, and ensure that those affected receive the attention and support they deserve.


Together, we can help build a future where all cancers, including those linked to inherited conditions, are recognised earlier, understood better, and treated more effectively.


Learn more:

 
 
bottom of page